Compare Neurocrine Biosciences Inc (NBIX) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NRG Energy Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while NRG Energy Inc trades at $106.93 (market cap $22.35B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and NRG Energy Inc for 62 Days on average.
| NBIX | NRG | |
|---|---|---|
Market Cap | $14.36B | $22.35B |
Volume | 1,237,180 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $185.50 | $184.03 |
52-Week Low | $123.10 | $95.23 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $14.37B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
NRG Energy (NRG) trades at $108.61, up 4.84% today, with a bullish technical signal and strong analyst consensus. Recent earnings showed a Q2 2026 miss but the company is executing a growth strategy including a 1.2 GW Texas data-center power project. Financials indicate solid revenue of $30.71B in 2025, though net margins are thin at 2.56%, and cash flow trends are volatile with a projected net outflow in 2026.
The outlook is positive given high analyst buy ratings and a $202.90 price target, but risks include execution on large capital projects, rising debt levels, and competitive pressures. Earnings growth from new assets and customer relationships remains the key catalyst for upside, though the stock faces near-term volatility from recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
